IL272074B2 - Peptide compounds and methods of treating diseases using same - Google Patents

Peptide compounds and methods of treating diseases using same

Info

Publication number
IL272074B2
IL272074B2 IL272074A IL27207420A IL272074B2 IL 272074 B2 IL272074 B2 IL 272074B2 IL 272074 A IL272074 A IL 272074A IL 27207420 A IL27207420 A IL 27207420A IL 272074 B2 IL272074 B2 IL 272074B2
Authority
IL
Israel
Prior art keywords
peptide
disease
isolated peptide
seq
peptides
Prior art date
Application number
IL272074A
Other languages
English (en)
Hebrew (he)
Other versions
IL272074A (en
IL272074B1 (en
Inventor
Cohen Ilana
Ovadia Eran
Ben-Shimon Avi
Original Assignee
Immunity Pharma Ltd
Cohen Ilana
Ovadia Eran
Avi Ben Shimon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunity Pharma Ltd, Cohen Ilana, Ovadia Eran, Avi Ben Shimon filed Critical Immunity Pharma Ltd
Priority to IL272074A priority Critical patent/IL272074B2/en
Priority to KR1020227028077A priority patent/KR20220145826A/ko
Priority to CN202411888870.7A priority patent/CN119708142A/zh
Priority to CN202411888873.0A priority patent/CN119708143A/zh
Priority to CN202180017719.4A priority patent/CN115942948B/zh
Priority to EP21704023.7A priority patent/EP4090347A1/en
Priority to CA3167139A priority patent/CA3167139A1/en
Priority to AU2021207415A priority patent/AU2021207415A1/en
Priority to US17/792,787 priority patent/US20230049549A1/en
Priority to BR112022013978A priority patent/BR112022013978A2/pt
Priority to PCT/IL2021/050044 priority patent/WO2021144798A1/en
Priority to CN202411888865.6A priority patent/CN119708140A/zh
Priority to CN202411888874.5A priority patent/CN119708144A/zh
Priority to CN202411888869.4A priority patent/CN119708141A/zh
Priority to JP2022542986A priority patent/JP7809060B2/ja
Priority to MX2022008746A priority patent/MX2022008746A/es
Publication of IL272074A publication Critical patent/IL272074A/en
Priority to CONC2022/0011101A priority patent/CO2022011101A2/es
Publication of IL272074B1 publication Critical patent/IL272074B1/en
Publication of IL272074B2 publication Critical patent/IL272074B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Gastroenterology & Hepatology (AREA)
IL272074A 2020-01-15 2020-01-15 Peptide compounds and methods of treating diseases using same IL272074B2 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
IL272074A IL272074B2 (en) 2020-01-15 2020-01-15 Peptide compounds and methods of treating diseases using same
BR112022013978A BR112022013978A2 (pt) 2020-01-15 2021-01-14 Peptídeo isolado, e, composição farmacêutica
PCT/IL2021/050044 WO2021144798A1 (en) 2020-01-15 2021-01-14 Peptide compounds and methods of treating diseases using same
CN202411888873.0A CN119708143A (zh) 2020-01-15 2021-01-14 肽化合物及其治疗疾病的方法
CN202180017719.4A CN115942948B (zh) 2020-01-15 2021-01-14 肽化合物及其治疗疾病的方法
EP21704023.7A EP4090347A1 (en) 2020-01-15 2021-01-14 Peptide compounds and methods of treating diseases using same
CA3167139A CA3167139A1 (en) 2020-01-15 2021-01-14 Peptide compounds and methods of treating diseases using same
AU2021207415A AU2021207415A1 (en) 2020-01-15 2021-01-14 Peptide compounds and methods of treating diseases using same
US17/792,787 US20230049549A1 (en) 2020-01-15 2021-01-14 Peptide compounds and methods of treating diseases using same
KR1020227028077A KR20220145826A (ko) 2020-01-15 2021-01-14 펩티드 화합물 및 이를 이용한 질병의 치료 방법
CN202411888870.7A CN119708142A (zh) 2020-01-15 2021-01-14 肽化合物及其治疗疾病的方法
CN202411888865.6A CN119708140A (zh) 2020-01-15 2021-01-14 肽化合物及其治疗疾病的方法
CN202411888874.5A CN119708144A (zh) 2020-01-15 2021-01-14 肽化合物及其治疗疾病的方法
CN202411888869.4A CN119708141A (zh) 2020-01-15 2021-01-14 肽化合物及其治疗疾病的方法
JP2022542986A JP7809060B2 (ja) 2020-01-15 2021-01-14 ペプチド化合物およびそれを用いる疾患の治療方法
MX2022008746A MX2022008746A (es) 2020-01-15 2021-01-14 Compuestos de peptidos y procedimientos de tratamiento de enfermedades que usan los mismos.
CONC2022/0011101A CO2022011101A2 (es) 2020-01-15 2022-08-04 Compuestos de péptidos y procedimientos de tratamiento de enfermedades que usan los mismos

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL272074A IL272074B2 (en) 2020-01-15 2020-01-15 Peptide compounds and methods of treating diseases using same

Publications (3)

Publication Number Publication Date
IL272074A IL272074A (en) 2021-07-29
IL272074B1 IL272074B1 (en) 2024-08-01
IL272074B2 true IL272074B2 (en) 2024-12-01

Family

ID=76863930

Family Applications (1)

Application Number Title Priority Date Filing Date
IL272074A IL272074B2 (en) 2020-01-15 2020-01-15 Peptide compounds and methods of treating diseases using same

Country Status (12)

Country Link
US (1) US20230049549A1 (enExample)
EP (1) EP4090347A1 (enExample)
JP (1) JP7809060B2 (enExample)
KR (1) KR20220145826A (enExample)
CN (6) CN119708144A (enExample)
AU (1) AU2021207415A1 (enExample)
BR (1) BR112022013978A2 (enExample)
CA (1) CA3167139A1 (enExample)
CO (1) CO2022011101A2 (enExample)
IL (1) IL272074B2 (enExample)
MX (1) MX2022008746A (enExample)
WO (1) WO2021144798A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL280101B2 (en) 2018-07-11 2025-05-01 Immunity Pharma Ltd Peptide compounds and their therapeutic uses

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
EP0928968A1 (en) 1998-01-12 1999-07-14 Universität Basel Screening method for apoptosis and necrosis
CA2443314C (en) 2001-04-03 2006-03-21 The Board Of Trustees Of The Leland Stanford Junior University Method of imaging cell death in vivo
WO2003037172A2 (en) * 2001-11-01 2003-05-08 Gpc Biotech Inc. Endothelial-cell binding peptides for diagnosis and therapy
AU2005276117C1 (en) * 2004-08-23 2013-04-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Peptide inhibitors for mediating stress responses
US8648045B2 (en) * 2005-03-10 2014-02-11 Ben Gurion University Of The Negev Research And Development Authority Ltd. VDAC1 compositions and methods of use thereof for regulating apoptosis
CA2737924A1 (en) * 2008-10-06 2010-04-15 Joshua Robert Schultz Methods of treating inflammation
US20130096070A1 (en) * 2009-04-07 2013-04-18 University Of Kansas Peptide targeting of inner ear cells
CA2836503C (en) * 2011-05-23 2020-09-22 Yeda Research And Development Co. Ltd. Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
BR112017022845A2 (pt) * 2015-04-23 2018-07-17 Nantomics, Llc neoepítopos de câncer
IL280101B2 (en) * 2018-07-11 2025-05-01 Immunity Pharma Ltd Peptide compounds and their therapeutic uses

Also Published As

Publication number Publication date
MX2022008746A (es) 2022-10-13
WO2021144798A1 (en) 2021-07-22
CN119708141A (zh) 2025-03-28
JP7809060B2 (ja) 2026-01-30
CN115942948A (zh) 2023-04-07
CA3167139A1 (en) 2021-07-22
EP4090347A1 (en) 2022-11-23
US20230049549A1 (en) 2023-02-16
CN119708142A (zh) 2025-03-28
CO2022011101A2 (es) 2022-11-08
AU2021207415A1 (en) 2022-09-08
CN119708144A (zh) 2025-03-28
JP2023510019A (ja) 2023-03-10
CN119708143A (zh) 2025-03-28
IL272074A (en) 2021-07-29
CN115942948B (zh) 2025-01-14
BR112022013978A2 (pt) 2022-10-11
CN119708140A (zh) 2025-03-28
KR20220145826A (ko) 2022-10-31
IL272074B1 (en) 2024-08-01

Similar Documents

Publication Publication Date Title
AU2012232642B2 (en) Neuroprotective peptides
RU2762089C2 (ru) ПЕПТИДЫ И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ, НАРУШЕНИЙ ИЛИ СОСТОЯНИЙ, АССОЦИИРОВАННЫХ С МУТАНТНЫМ р53
AU2024278477A1 (en) Peptide compounds and therapeutic uses of same
IL272074B2 (en) Peptide compounds and methods of treating diseases using same
RU2843553C2 (ru) Пептидные соединения и их терапевтическое применение
EA044784B1 (ru) Пептидные соединения и способы лечения заболеваний с их использованием
RU2812775C2 (ru) Пептидные соединения и их терапевтическое применение
EA051325B1 (ru) Пептидные соединения и их терапевтическое применение
EA046208B1 (ru) Пептидные соединения и их терапевтическое применение
US20220251159A1 (en) Peptides and use of same in the treatment of diseases, disroders or conditions associated with a mutant p53